BÜHLMANN

Quantum Blue[®] Anti-Adalimumab

Qualitative Lateral Flow Assay

For research use only. Not for use in diagnostic procedures.

> LF-ADAD25-U 25 tests LF-ADAD10-U 10 tests

> > Release date: 2023-04-27 Version A4

Manufacturer BÜHLMANN Laboratories AG Baselstrasse 55 4124 Schönenbuch, Switzerland Tel.: +41 61 487 1212 Fax: +41 61 487 1234 info@buhlmannlabs.ch

INTENDED USE

The Quantum Blue[®] Anti-Adalimumab test is a qualitative immunoassay for the detection of anti-adalimumab antibodies in human serum samples. Quantum Blue[®] Anti-Adalimumab is combined with the Quantum Blue[®] Reader.

For research use only. Not intended for use in diagnostic procedures.

PRINCIPLE OF THE ASSAY

The test is designed for the selective measurement of anti-adalimumab antibodies by a sandwich immunoassay. The signal intensities of the test line (T) and the control line (C) are measured by the Quantum Blue[®] Reader. The results are reported as negative <neg(-)> or positive <pos(+)>.

Quantity Code Comments Reagents LF-ADAD25-U LF-ADAD10-U Vacuum-B-LFADAD-Test sealed in a 25 pieces 10 pieces Cassette foil bag TC pouch 1 bottle 1 bottle Chase **B-LFADAD-**Ready to Buffer CB use 10 mL 10 mL Dilute 1:10 Controls 2 vials 2 vials **B-LFADAD**in chase Low* / CONSET 0.1 mL 0.1 mL buffer High* before use **RFID Chip B-LFADAD-**White 1 piece 1 piece RCC plastic card Card **RFID** Chip **B-LFADAD-**Green 1 piece 1 piece Card RCC15 plastic card Barcode **B-LFADAD-**2D Barcode 1 piece 1 piece Card BCC plastic card Table 1

REAGENTS SUPPLIED AND PREPARATION

 * Controls are lot-specific. The controls low and high should be reported as <neg(-)> and <pos(+)> respectively.

CHECK YOUR TEST KIT

BÜHLMANN products have been manufactured with the greatest of care and all possible efforts have been taken to ensure completeness of this test kit and its performance. Nevertheless, we advise you to verify your test kit for the condition of the test cassette and its pouch based on the following criteria:

- Expiration date
- The fault-free condition of the pouch (e.g. absence of any perforation that could be caused by improper handling).
- The fault-free condition of the test cassette (e.g. absence of scratches on the analytical membrane).

Should one of the test cassettes not fulfil the criteria mentioned above, please use another test cassette.

STORAGE AND SHELF LIFE OF REAGENTS

Unopened reagents

Store at 2-8 $^{\circ}\text{C}.$ Do not use the reagents beyond the expiration date printed on the labels.

Opened reagents Test Cassette Test cassettes removed from the foil pouch must be used within 4 hours. Chase Buffer Store for up to 6 months at 2-8 °C after opening.

Controls Low / High Store for up to 6 months at 2-8 °C after opening.

Table 2

MATERIALS REQUIRED BUT NOT PROVIDED

- Vortex mixer
- Timer (optional)
- Precision pipettes with disposable tips: 10-100 μL and 100-1000 μL
- Eppendorf tubes (or equivalent) for dilution of serum samples
- Quantum Blue[®] Reader available from BÜHLMANN (order code: BI-POCTR-ABS)
- Gloves and laboratory coat

WARNINGS AND PRECAUTIONS

Safety precautions

- Specimens should be handled as if capable of transmitting infections and should be handled in accordance with Good Laboratory Practice (GLP) using appropriate precautions.
- The controls and chase buffer of this kit contain components classified in accordance with the Regulation (EC) No. 1272/2008: 2-methyl-4isothiazolin-3-one hydrochloride (conc. ≥ 0.0015%), thus the reagents may cause allergic skin reactions (H317).
- Avoid contact of reagents with the skin, eyes, or mucous membranes. If contact does occur, immediately wash with generous amounts of water; otherwise, irritation can occur.
- Unused solution should be disposed according to local state and federal regulations.

Technical precautions

Kit components

- <u>The test must be performed at room temperature</u> (20-26 °C).
- All reagents and test samples must be equilibrated to room temperature before starting the assay.
- Once equilibrated to room temperature remove the test cassette from the foil pouch. Allow the test cassette to equilibrate in the laboratory environment for at least 2 minutes before starting the assay.
- Mix well (e.g. vortex) the reagents before use.
- Components must not be used after the expiration date printed on the labels.
- Do not mix different lots of reagents.
- Do not disassemble the test cassettes.

- Test cassettes cannot be re-used.
- Handle the test cassettes with care. Do not contaminate the sample loading port or read-out window via skin contact, other liquids, etc. (figure 1D).
- Ensure a flat, horizontal position of the test cassette while performing the assay.

Test procedure

- Read the instructions carefully prior to carrying out the test. Test performance will be adversely affected if reagents are incorrectly diluted, handled or stored under conditions other than those detailed in this instruction for use.
- Please note that there are two generations of readers: The Quantum Blue[®] Reader 2nd Generation with serial numbers between 1000 and 3000 (QB2) and Quantum Blue[®] Reader 3rd Generation with serial numbers above 3000 (QB3G).
- The QB2 must be switched on and programmed for the Quantum Blue[®] Anti-Adalimumab assay: Load the assay method using the RFID chip card (B-LFADAD-RCC or B-LFADAD-RCC15), before starting the assay (see Quantum Blue[®] Reader manual).
- The QB3G must be switched on and programmed for the Quantum Blue[®] Anti-Adalimumab assay either by using the barcode card (B-LFADAD-BCC) or by selecting from the test menu (Fast Track Mode only). For more information please refer to the Quantum Blue[®] Reader manual.
- Use the RFID chip card (QB2) / barcode card (QB3G) in order to change lot-specific test parameters.
- Samples that are not properly handled may cause inaccurate results.
- Diluted samples should be measured promptly and cannot be stored longer than 15 hours at room temperature (≤23 °C).

SPECIMEN COLLECTION AND STORAGE

Collect blood into plain venipuncture tubes without any additives and avoid hemolysis. Perform serum preparation according to manufacturer's instructions. Decant the serum.

Undiluted serum samples can be stored unrefrigerated (temperatures up to 28 °C) for up to 9 days or stored cooled (2-20 °C) for 15 days. For longer storage, keep undiluted serum samples at \leq -20 °C. The samples are stable for at least 13 months at \leq -20 °C. More than six freeze-thaw cycles should be avoided.


ASSAY PROCEDURE

For the assay use only reagents equilibrated to room temperature. The test cassette must be removed from the foil pouch prior to assay start.

The assay procedure consists of two steps:

1. Dilution of serum samples and controls with chase buffer


Prior to measurement dilute the serum sample and controls 1:10 with chase buffer (B-LFADAD-CB) (e.g. mix 20 μ L serum sample or control with 180 μ L chase buffer in a test tube) and mix by vortexing, pipetting or shaking.



2. Lateral flow assay procedure and readout

QB2

Two alternative methods can be loaded from the respective RFID chip card: B-LFADAD-RCC15 (with internal timer) or B-LFADAD-RCC (without internal timer). Select one of the RFID chip cards before starting the experiments. Load the test method from the RFID chip card on the Quantum Blue[®] Reader.



QB3G

Two different modes of operation are available to measure samples with the QB3G: Fast Track Mode or Fail Safe Mode. Before starting the assay, please inform yourself in which operation mode your reader is working.

The test method can be loaded from the barcode card (Fast Track and Fail Safe Mode) or, if previously used, selected from the test menu (Fast Track Mode only). Measurements can be performed with or without an internal timer in the Fast Track Mode. Measurements in the Fail Safe Mode can be performed with internal timer only.

Follow the instructions provided on the screen of the QB3G. You may also refer to the QB3G Quick Guides for the Fast Track and Fail Safe Mode.




2.1. Method with internal timer

<u>QB2</u>: Use the green RFID chip card B-LFADAD-RCC15

<u>QB3G (Fast Track Mode)</u>: when prompted by the QB3G to skip the incubation time, select "NO"

QB3G (Fail Safe Mode): default setting

- Unpack the test cassette. Allow the test cassette to equilibrate in the laboratory environment for at least 2 minutes.
- Add 80 µL of the diluted serum sample onto the sample loading port of the test cassette (figure 1D).
- Insert the test cassette into the test cassette holder of the Quantum Blue[®] Reader.
- Close the test cassette holder and start the measurement by pressing the start button on the QB2 or the "Start Measurement" option on the QB3G.
- The scan starts automatically after 15 minutes.
- For low / high controls: Repeat step 2.1 using 80 µL of diluted controls instead of diluted serum.



2.2. Method without internal timer

QB2: Use the white RFID chip card B-LFADAD-RCC

<u>QB3G (Fast Track Mode)</u>: when prompted by the QB3G to skip the incubation time, select "YES"

<u>QB3G (Fail Safe Mode)</u>: option not available

- Unpack the test cassette. Allow the test cassette to equilibrate in the laboratory environment for at least 2 minutes
- Add 80 µL of the diluted serum sample onto the sample loading port of the test cassette (figure 1D).
- Incubate for 15 ± 1 minute (set a timer manually).
- Insert the test cassette into the test cassette holder of the Quantum Blue[®] Reader.
- Scan the test cassette with the Quantum Blue[®] Reader by pressing the start button on the QB2 or the "Start Measurement" option on the QB3G.

 For low / high controls: Repeat step 2.2 using 80 µL of diluted controls instead of diluted serum.



<u>Remark</u>: Please refer to the Quantum Blue[®] Reader manual to learn about the basic functions and how to initialize and operate the Quantum Blue[®] Readers, especially how to select test methods and how to load lotspecific parameters from the RFID chip card (QB2) / barcode card (QB3G) on the Quantum Blue[®] Reader. Ensure the correct insertion of the test cassette into the Quantum Blue[®] Reader, with the read-out window first (figure 1D).

QUALITY CONTROL

- If the performance of the assay does not correlate with the established limits and repetition excludes errors in technique, check the following issues: *i*) pipetting, temperature controlling and timing *ii*) expiration dates of reagents and *iii*) storage and incubation conditions.
- The result of the self-test of the Quantum Blue[®] Reader performed at the startup of the instrument has to be valid.

STANDARDIZATION

- The calibrator material is a monoclonal antiadalimumab human IgG antibody in a human serum matrix.
- The Quantum Blue[®] Reader uses a lot-specific calibration curve to calculate the anti-adalimumab concentration in equivalents ($\mu g_{eq}/mL$) to the monoclonal anti-adalimumab IgG calibrator. The 95% confidence interval of the combined uncertainty of the product calibrator is lower than 25.0%, the combined uncertainty of the controls lower than 30.0%.
- The Quantum Blue[®] Reader indicates the result as negative <neg(-)>, if the sample concentration is below 0.2 μg_{eq}/mL. Results equal to and above 0.2 μg_{eq}/mL are indicated as positive <pos(+)>.

VALIDATION OF RESULTS

- For a valid test result, the control line (C) must be visible in any case (see figure 1A and figure 1B). It is used as a functional test control only and cannot be used for the interpretation of the test line (T). If the test line (T) is not detectable after 15 minutes of incubation time (figure 1A), the concentration of anti-adalimumab antibodies present in the serum sample is below the detection limit. If a test line (T) is detectable after 15 minutes of incubation time (figure 1B), the anti-adalimumab antibody concentration present in the serum sample is calculated by the Quantum Blue[®] Reader.
- If only the test line (T) is detectable after 15 minutes of incubation time (figure 1C), the test result is invalid and

the Quantum Blue[®] Anti-Adalimumab assay has to be repeated using another test cassette.

- If neither the control line (C) nor the test line (T) are detectable after 15 minutes of incubation time (figure 1D), the test result is invalid and the Quantum Blue[®] Anti-Adalimumab assay has to be repeated using another test cassette.
- As the Quantum Blue[®] Reader allows an evaluation of the test (T) and control (C) line, an additional validity check of the control line (C) is undertaken. If the signal intensity of the control line (C) is below a specific preconfigured threshold after 15 minutes of incubation time, the test result is also invalid and the Quantum Blue[®] Anti-Adalimumab assay has to be repeated using another test cassette.

LIMITATIONS

- The Quantum Blue[®] Anti-Adalimumab test is a drugsensitive assay and therefore can only be used on samples with undetectable adalimumab concentrations.
- The reagents supplied with this kit are optimized to measure levels of anti-adalimumab antibodies in serum samples.

DISPLAY OF RESULTS

The Quantum Blue[®] Reader displays the following result categories for the Quantum Blue[®] Anti-Adalimumab assay:

| Display | Concentration of Anti-Adalimumab | | |
|---------|----------------------------------|--|--|
| neg(-) | <0.2 µg _{eq} /mL | | |
| pos(+) | ≥0.2 µg _{eq} /mL | | |
| | Table 3 | | |

PERFORMANCE CHARACTERISTICS

The following performance characteristics have been established with the Quantum Blue[®] Reader 2nd and 3rd Generation.

Indicated performance characteristics apply for both reader generations.

Method comparison Assay agreement: 91.3%

One hundred and twenty (120) samples were measured with 2 lots of the Quantum Blue[®] Anti-Adalimumab assay over 4 days, resulting in 240 values, out of which 42 were negative and 198 were positive. The same samples were measured in duplicate using a commercially available ELISA assay. Mean ELISA values were classified as positive or negative according to the indicated cut-off and the total agreement between both assays was calculated. The results are summarized in table 4.

Within-laboratory precision: 100% within-category

Repeatability and within-laboratory precision were established according to the CLSI guideline EP05-A3 using the standard 20 days x 2 runs x 2 replicates study design (ref. 1). Three (3) pooled serum samples: negative, low positive and high positive, were assayed. The results are summarized in table 5.

Reproducibility: 100% within-category

Reproducibility was established according to the CLSI guideline EP05-A3 using a 3 instruments / lots / operators x 5 days x 5 replicates study design (ref. 1). Three (3) pooled serum samples: negative, low positive and high positive, were assayed. The results are summarized in table 6.

Limit of Detection (LoD): 0.1 µg_{eq}/mL

The LoD was established according to the CLSI guideline EP17-A2 and with proportions of false positives (α) less than 5% and false negatives (β) less than 5% based on 120 determinations, with 60 blank and 60 low level replicates; and a LoB of 0.0 μ geq/mL (ref. 2).

High dose hook effect

No negative results for contrived samples with theoretical anti-adalimumab concentrations of up to 592.5 $\mu g_{eq}/mL$ were observed. The study was performed with two Quantum Blue[®] Anti-Adalimumab lots.

INTERFERING SUBSTANCES

The susceptibility of the Quantum Blue[®] Anti-Adalimumab test to interfering substances was assessed according to the CLSI-approved guideline EP07-A2 (ref. 3). At least 7 replicates per interferent were tested. An out of category result for a single replicate was considered interference.

TNFα blocker

No interference was detected with the following substance at the listed concentration: infliximab (Remicade[®], 10 µg/mL). Interferences were detected with the substance adalimumab (Humira[®], 15 µg/mL). The interference effect was further characterized by a dose response test. Results indicate that anti-adalimumab presence can only be assessed in samples with undetectable adalimumab levels.

Serum indices


No interference was detected with the following substances, up to the listed concentrations: triglycerides (Intralipid[®] 1320 mg/dL; equivalent to 37 mmol/L triglyceride), conjugated bilirubin (342 μ mol/L; 29 mg/dL), unconjugated bilirubin (342 μ mol/L; 20 mg/dL), Hemoglobin (200 g/L) and rheumatoid factors (up to 600 IU/mL).

Immunosuppressive and other medications

No interference was detected with the following substances, up to the listed concentrations: azathioprine (10.8 μ mol/L, 3.0 μ g/mL), 6-mercaptopurine (13.1 μ mol/L, 2.0 μ g/mL), and methotrexate (149.6 μ mol/L, 68.0 μ g/mL)

TABLES AND FIGURES

Test Results



Method Comparison

| | | Comparator | | |
|--|----------|------------|----------|-------|
| | | Negative | Positive | Total |
| Quantum Blue [®] Anti- Adalimumab | Negative | 19.2% | 6.3% | 25.4% |
| | Positive | 2.5% | 72.1% | 74.6% |
| | Total | 21.7% | 78.3% | 100% |
| | | | | |

91.3%

Table 4

Repeatability / Within-Laboratory Precision

| Sample | Description | n | Mean conc. [µg _{eq} /mL] | % Within category |
|--------|---------------|----|--------------------------------------|----------------------|
| S1 | Negative | 80 | 0.0 | 100 |
| S2 | Low Positive | 80 | 0.3 | 100 |
| S3 | High Positive | 80 | 1.4 | 100 |
| | | | | |

Table 5

Reproducibility

| Sample | Description | n | Mean conc. [µg _{eq} /mL] | % Within category |
|--------|---------------|----|--------------------------------------|----------------------|
| S1 | Negative | 75 | 0.0 | 100 |
| S2 | Low Positive | 75 | 0.4 | 100 |
| S3 | High Positive | 75 | 2.0 | 100 |

Table 6

REFERENCES

1. CLSI. Evaluation of Precision of Quantitative Measurement Procedures; Approved Guideline - Third Edition. CLSI document EP05-A3. Wayne, PA: Clinical and Laboratory Standards Institute; 2014.

2. CLSI. Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures; Approved Guideline - Second Edition. CLSI document EP17-A2. Wayne, PA: Clinical and Laboratory Standards Institute; 2012.

3. CLSI. *Interference Testing in Clinical Chemistry; Approved Guideline - Second Edition.* CLSI document EP07-A2. Wayne, PA: Clinical and Laboratory Standards Institute; 2005.

CHANGELOG

| Date | Version | Change |
|------------|---------|---|
| 2023-04-27 | A4 | Update to chapter <i>Warnings and precautions</i> Inclusion of uncertainty values for product calibrator and controls in chapter <i>Standardization</i> Revision of chapter <i>Symbols</i> |

SHIPPING DAMAGE

Please notify your distributor, if this product was received damaged.

SYMBOLS

BÜHLMANN use symbols and signs listed and described in ISO 15223-1. In addition the following symbols and signs are used:

| Symbol | Explanation |
|-----------|----------------|
| TC | Test Cassette |
| BUFICHASE | Chase Buffer |
| CONTROLL | Control Low |
| CONTROLH | Control High |
| RCC | RFID Chip Card |
| BCC | Barcode Card |